Olanzapine/fluoxetine

Drug Profile

Olanzapine/fluoxetine

Alternative Names: OFC; Symbyax; ZypZac

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antidepressants; Antipsychotics; Benzodiazepines; Propylamines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Bipolar disorders; Major depressive disorder

Most Recent Events

  • 21 Jun 2012 First Generic equivalent available in USA for Bipolar disorders and Major depressive disorder
  • 31 Mar 2012 Eli Lilly completes a phase III trial in Major depressive disorder in Argentina, India, Mexico, Puerto Rico, Russia, South Africa, Turkey and USA (NCT00958568)
  • 23 Mar 2009 Launched for Depression in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top